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 1 
Abstract 2 
Ivermectin serves as a good addition to the small group of medications for soil-3 
transmitted helminths, particularly Trichuris trichiura infections. So far, ivermectin has been 4 
poorly characterized in clinical trials to treat T. trichiura; especially information on its 5 
pharmacokinetic (PK) behavior in infected pediatric populations is missing. Existing 6 
approaches to quantify ivermectin in human matrices are time-consuming, limited to matrixes 7 
of high volume, which excludes the more ethical micro-blood sampling and mostly do not 8 
distinguish between ivermectin and its metabolites. Thus, a sensitive, selective and rapid 9 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to 10 
quantify ivermectin extracted from dried blood spots (DBS), plasma and blood. Method 11 
validation was performed on accuracy, precision, sensitivity, selectivity, linearity and stability. 12 
While the quantification of ivermectin in plasma and DBS were successfully validated, blood 13 
samples failed validation due to insufficient stability and robustness. The method was applied 14 
to samples from a clinical study with 11 adult volunteers from rural Côte d’Ivoire infected with 15 
T. trichiura sampled at 11 time points. Good agreement of the time-concentration profiles and 16 
PK parameters of plasma and DBS samples were achieved with e.g., a maximal 17 
concentration of 51.6 and 40.1 ng/mL, respectively and identical time to reach maximal 18 
concentration of 3.9 h. Comparison of the results by Bland-Altman analysis resulted in high 19 
consistency. The less invasive and more patient-friendly DBS micro-blood sampling 20 
technique will be useful in future clinical trials to evaluate ivermectin’s PK profile in larger 21 
populations. 22 
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 1 
1. Introduction  2 
The avermectin family was discovered in the 1970s and soon thereafter, the derivative 3 
ivermectin was developed revealing superior activity against many parasitic worms.1,2 In 4 
1981, ivermectin was approved to the market as a veterinary anthelminthic drug and in 1987 5 
it was first utilized in human medicine to treat Onchocerca volvulus. Donation and mass drug 6 
administration programs were soon thereafter initiated to deliver ivermectin to Africa and 7 
South America to reach onchocerciasis and a few decades later lymphatic filariasis 8 
patients.1,3 In tropical and sub-tropical settings, co-infections are common and hence, 9 
additional efficacy was documented against other parasitic infections including the soil-10 
transmitted helminths (STH).4,5 The number of infected individuals with STHs is estimated at 11 
1.5 billion and the recommended drugs against STH infections (albendazole, mebendazole, 12 
pyrantel pamoate and levamisole) have only poor effect on Trichuris trichiura.6,7  13 
Ivermectin, however, is still, despite its large-scale use rather poorly characterized for 14 
human use.8 A few clinical studies have been performed on T. trichiura including ivermectin 15 
or ivermectin co-administration to further evaluate its efficacy against STH infections.9,10 16 
However, further evidence is required to fully understand the pharmacokinetic (PK) and –17 
dynamic profile of ivermectin in correlation to different doses and safety. Even though some 18 
PK studies of ivermectin have been performed, all of them included a low number of 19 
exclusively adult volunteers who were healthy or infected with Onchocerca volvulus.11–18 20 
Venous blood sampling was performed in these studies to obtain plasma samples, the only 21 
matrix that has been used for ivermectin PK analysis so far. Given the broad interest of the 22 
use of ivermectin as treatment for T. trichiura, scabies as well as an agent to reduce malaria 23 
transmission,19,20 additional PK studies are required, including children, which are the primary 24 
focus for the treatment of STH infections. However, when children are participating in a 25 
clinical trial, venous blood sampling is challenging and unethical. Micro-blood sampling (e.g., 26 
the dried blood spot (DBS) technique) offers an appropriate alternative for PK studies in this 27 
vulnerable population. It is less invasive, less painful, simpler and more rapidly to perform. 28 
Additionally, DBS do not require cooling or freezing and are less likely to cause an infection 29 
risk for nurses and researchers.21–23 However, a micro-blood sampling technique has not yet 30 
been established for the quantification of ivermectin. 31 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for 32 
drug quantification. Nevertheless, most analytic methods to quantify ivermectin have been 33 
established by high-performance liquid chromatography (HPLC), where the drug was reacted 34 
to a fluorescent counterpart.14,24–26 Even though ivermectin is only poorly metabolized, the 35 
established HPLC methods do not distinguish between ivermectin and its metabolites as all 36 
compounds are derivatized. Only Kitzman et al. developed a HPLC method, which is 37 
sufficiently long to separate and quantify ivermectin only.13 However, a single run of 32 38 
minutes is not applicable when a large number of samples is analyzed. The analysis of 39 
ivermectin in plasma, milk or other matrices by mass spectrometry has been described but 40 
the methods cannot be applied to micro-blood samples because large sample volumes are 41 
required.27–30 42 
For the first time, an analytical LC-MS/MS method was developed and validated for the 43 
quantification of ivermectin from DBS samples. For comparison, the analytical method was 44 
also established for plasma and blood matrices. A PK study with 11 adult volunteers from 45 
rural Côte d’Ivoire infected with T. trichiura was performed. Participants received orally the 46 
standard dose of ivermectin (200 µg/mL) and both DBS and venous samples were withdrawn 47 
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at 11 time points post-treatment. Ivermectin was extracted and quantified to illustrate the 1 
robustness of the DBS sampling method and the comparability to plasma concentrations.  2 
 3 
2. Materials and Methods 4 
 5 
2.1 Chemicals and material 6 
Ivermectin (powder, 96% B1A), formic acid (LC-MS grade) and ammonium acetate (LC-7 
MS grade) were purchased from Sigma-Aldrich (Buchs, Switzerland). Ivermectin-d2 was 8 
synthesized by Toronto research chemicals (Ontario, Canada). Ivermectin tablets (3 mg) 9 
were kindly provided by ELEA (Buenos Aires, Argentina). Ultrapure water was prepared 10 
using a Millipore water purification system (Milli-Q® Advantage A10, Merck, Darmstadt, 11 
Germany). LC-MS grade solvents, acetonitrile and isopropanol, and Whatman® protein 12 
saver cards 903 were purchased from Merck KGaA (Darmstadt, Germany). SOLAµ solid 13 
phase extraction (SPE) plates HPR were obtained from Thermo Fisher Scientific (Reinach, 14 
Switzerland). Ivermectin stock solutions were prepared and extraction steps performed in 15 
protein low-binding material (Vaudaux-Eppendorf AG, Basel, Switzerland).  16 
2.2 LC-MS/MS instrumentation and settings 17 
Fragment separation and identification was performed on a 1260 Infinity LC System 18 
connected to a 6460 triple quad LC-MS (Agilent Technologies, Santa Clara, CA, USA). The 19 
autosampler Thermostat (1200 series, Agilent Technologies) was used for sample injection 20 
and cooling (4 ºC).  21 
Fragment specific mass spectrometer parameters were optimized by direct infusion of 22 
1 µg/mL ivermectin dissolved in acetonitrile to the mass spectrometer and are summarized in 23 
table 1. Selected reaction monitoring (SRM) of the positively charged fragment of ivermectin 24 
and ivermectin-d2 was performed for detection (figure 1). The general settings of the mass 25 
spectrometer were as follows: gas temperature 250 ºC, gas flow 5 L/min, nebulizer 30 psi, 26 
sheath gas temperature 300 ºC, sheath gas flow 11 L/min, and capillary voltage 5000 V. 27 
Liquid chromatography was performed on a Luna C8 column (30 x 2.0 mm, 3 µm particle 28 
size, 100 Å; Phenomenex, Torrance, CA USA). Ammonium acetate prepared with ultrapure 29 
water (mobile phase A, 0.4 mM) and acetonitrile (mobile phase B) served as eluents. Formic 30 
acid was added to both eluents (0.1% v/v). A gradient elution was performed (table 2) with a 31 
flow rate of 0.5 mL/min. The autosampler syringe and injection valve was cleaned three 32 
times with isopropanol-H2O (1:1 v/v) after each sample injection. The software Agilent 33 
MassHunter Quantitative Analysis was used for data analysis.   34 
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 1 
Figure 1. Molecular structure of (A) ivermectin and (B) ivermectin-d2. 2 
                3 
Table 1. Fragment specific mass spectrometry parameters. 4 
Parameter 
Product Ion 307 
Ivermectin 
Product ion 571 
Ivermectin-d2 
Dwell 100 80 
Fragmentor voltage 135 135 
Collision Energy 20 8 
Cell accelerator voltage 6 2 
 5 
Table 2. Gradient elution of liquid chromatography. 6 
Time (min) 
Mobile 
phase B (%) 
0.00 40 
0.20 40 
0.50 95 
2.50 95 
2.55 40 
4.00 40 
 7 
2.3 Blood, plasma and dried blood spot (DBS) sample procession 8 
 9 
2.3.1 Preparation of calibration and quality control samples 10 
Human blood was obtained from the local blood donation center (Basel, Switzerland) and 11 
kept in heparin coated vacutainer tubes to prevent coagulation of blood. The stock solution of 12 
ivermectin was prepared in acetonitrile (1 mg/mL) and stored at -20 ºC. Working solutions of 13 
ivermectin were obtained by serial dilutions in acetonitrile:H2O (1:1 v/v). Quality control (QC) 14 
and calibration samples were prepared by spiking plasma, blood and DBS with working 15 
solutions (50:1 v/v) in the range of 2–200 ng/mL. The final concentration of organic solvent in 16 
the spiked plasma and blood samples was < 2%.  17 
According to FDA guidelines, each validation set of samples consisted of at least eight 18 
calibration samples (including the lower limit of quantification (LLOQ) and the upper limit of 19 
quantification (ULOQ)), six blank samples (matrix without internal standard) and six zero 20 
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samples (matrix with internal standard).31 Additionally, six QC replicates at the LLOQ, low, 1 
medium and high concentration covering the whole calibration range were included in each 2 
experiment. QC and calibration samples derived from plasma were always spiked freshly on 3 
the day of analysis, blood and DBS samples were prepared and stored at -20 ºC. 4 
QC samples, 2, 3, 100 and 180 ng/mL for plasma analysis and 3, 5, 100 and 180 ng/mL 5 
for blood and DBS samples, were included in each run. QC samples were always prepared 6 
in six replicates of different human sources.  7 
2.3.2 Sample extraction 8 
The stock solution of ivermectin-d2 (internal standard, 1 mg/mL) was prepared in 9 
acetonitrile and stored at -20 ºC. The extraction solvent 1 (acetonitrile/H2O (4:1 v/v), ES1) 10 
and 2 (acetonitrile/H2O (5:1 v/v), ES2) were spiked with 0.01 ng of the internal standard. 11 
100 µL plasma or blood samples were mixed with 100 µL or 120 µL of the extraction solvent 12 
ES1 or ES2, respectively and agitated for 10 min at 2000 rpm at room temperature (rt).  13 
Two circular spots (ø 8 mm) were punched from each DBS card, 400 µL H2O was 14 
added and agitated at rt for 10 min at 2000 rpm. Then, 400 µL of ES1 was added and again 15 
agitated under the same conditions. Thereafter, DBS samples were sonicated in an 16 
ultrasonic bath (TPC-280, M. Scherrer AG, Zuzwil, Switzerland) for 15 min at rt.  17 
The samples (plasma, blood and DBS) were centrifuged for 10 min at 3000 x g. The 18 
supernatant was transferred to a pre-conditioned SPE-96 well plate. According to the 19 
manufacturer’s protocol, SPE plates were first equilibrated with 200 µL acetonitrile, followed 20 
by conditioning with 200 µL H2O. Once the samples were loaded onto the columns, they 21 
were washed with 25% acetonitrile and eluted twice in 25 µL acetonitrile. 10 µL of each 22 
sample was injected to the LC-MS/MS system for analysis.  23 
2.3.3 Impact of hematocrit on DBS and blood sample analysis 24 
The effect of hematocrit was evaluated for DBS and blood sample analysis. The 25 
hematocrit of QC samples (n = 6 from different human donors) was adjusted with plasma to 26 
20–50% to cover the hematocrit range expected in the study population. Calibration samples 27 
were prepared with 35% or 40% hematocrit. The hematocrit values of QC samples were 28 
adjusted in all experiments to ensure accuracy and precision of the method.  29 
2.4 Method validation 30 
Method validation for the analysis of ivermectin was performed according to the U.S. FDA 31 
guidelines and the following characteristics were validated: stability, selectivity, sensitivity, 32 
accuracy, precision, recovery, matrix effect and linearity.31  33 
2.4.1 Stability 34 
Different conditions of field and laboratory work were mimicked to test the stability of 35 
ivermectin in blood, plasma and DBS. Extracted ivermectin samples were incubated at rt for 36 
4 h and at 4 ºC for 72 h (autosampler stability). One set of spiked samples was stored at -37 
80 ºC for 2 months (long-term stability) and another set was three times frozen for 24 h at -38 
80 ºC followed by thawing to rt (freeze-thaw cycles). Additionally, long-term stability at rt was 39 
evaluated for DBS cards (2–3 months). QC samples (low, middle and high) were prepared 40 
and kept under the specified conditions. Extracted samples were analyzed and compared to 41 
calibration samples. Ivermectin was considered stable when the results did not deviate more 42 
than ± 15% from the nominal value of freshly prepared calibrators.  43 
2.4.2 Selectivity and Sensitivity 44 
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Blank human plasma and DBS samples were processed from six different human 1 
sources to validate the limit of detection (LOD) of each matrix. The signal of LLOQ should be 2 
at least 5x of LOD and should not deviate more than ± 20% from the nominal concentration.  3 
2.4.3 Accuracy, Precision 4 
The accuracy and precision of the analytical method was tested with four QC 5 
concentrations (LLOQ, low, medium and high) each prepared in six replicates of different 6 
blood or plasma sources. Within-run (intra-assay) assessed the precision and accuracy of 7 
three validation sets in a single analytical run and between-run (inter-assay) recorded three 8 
validation sets on three different days. Results were compared to the nominal value obtained 9 
from calibration samples. The results of QC samples were accepted when 4/6 samples were 10 
within ± 15% of the nominal value and within ± 20% of the nominal value for the LLOQ. 11 
Accuracy is presented as the percentage ratio of measured to the nominal concentration and 12 
precision is illustrated as the coefficient of variation (CV [%]).  13 
2.4.4 Recovery and matrix effect 14 
Relative recovery (RRE) and matrix effect (ME) were analyzed with samples of four 15 
human sources. QC sample concentrations (low, medium and high) were prepared for 16 
analyzing RRE and ME. RRE is obtained by comparing zero blank plasma or DBS that is 17 
spiked with ivermectin after extraction to the corresponding extracted samples. ME was 18 
determined by comparing extracted zero blank matrix that is spiked after extraction to the 19 
corresponding ivermectin concentrations prepared in acetonitrile.  20 
2.4.5 Linearity 21 
Calibration samples were accepted when 75% of the samples were ± 15% (± 20 for 22 
LLOQ) of the nominal value. The coefficient of determination (r2) had to be ≥ 0.99. 23 
2.5 Method application 24 
The validated LC-MS/MS method was applied to samples of a PK clinical trial in rural 25 
Côte d’Ivoire with 11 adult volunteers (≥ 18 years of age) infected with T. trichiura. Diagnosis 26 
was performed by analyzing stool samples with the Kato Katz technique. Participants were 27 
orally treated with the standard dose of 200 µg/kg ivermectin. Ethical approval was obtained 28 
from the Ethical Committee of Northwestern and Central Switzerland (2017-00250) and the 29 
Comité d’Ethique et de la Recherche of the Ministry of Health in Côte d’Ivoire 30 
(052/fMSHP/CNER-kp). Informed consent was obtained from all patients. The study was 31 
registered at the ISRCTN registry (no. ISRCTN15871729). 32 
Patients received a fatty breakfast (oily fish on bread) since a fatty meal is known to 33 
enhance ivermectin’s bioavailability.32 Venous and micro-blood sampling was performed at 34 
0, 1, 2, 4, 6, 7, 8, 9, 24, 48, 72 h post-treatment. Venous blood (~4 mL) was collected in 35 
EDTA covered vacutainer tubes (BD, Allschwil, Switzerland) to prevent coagulation. The 36 
blood was centrifuged to obtain plasma. Plasma samples were stored at -20 ºC at the clinical 37 
trial site. Additionally, microsampling was performed at the same time points by taking 38 
capillary blood from the same individuals. Sterile finger-prickers were used to puncture the tip 39 
of a finger obtaining a blood drop. Lithium heparin coated capillaries were loaded with blood, 40 
which was dropped onto DBS cards (~60 µL per spot). This was performed in four replicates 41 
for each patient and time point. The DBS were allowed to dry for at least 2 h and then stored 42 
at -20 ºC at the clinical trial site in sealed plastic bags containing silica desiccants. Plasma 43 
and DBS samples were shipped to Basel, Switzerland with dried ice and stored at -80 ºC 44 
until processed for analysis. 45 
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 1 
2.6 Data analysis 2 
 3 
The following PK parameters were obtained by non-compartmental analysis using 4 
WinNonlin (5.2, Certara, Princeton, NJ, USA): maximum ivermectin concentration (Cmax), 5 
time to reach Cmax (tmax), time in which half of the absorbed drug is eliminated (half-life t1/2), 6 
area under the curve determined until last positive concentration (AUC).  7 
Bland-Altman analysis was performed to evaluate the agreement between plasma vs 8 
DBS samples. The difference (%) of ivermectin concentration extracted from the matrixes 9 
was plotted vs the average concentration. Additionally, an unpaired t test was performed 10 
following a F test to compare variances of PK parameters. Statistical analysis was performed 11 
with Prism 6.01 (GraphPad, CA, USA).  12 
 13 
3. Results and Discussion 14 
 15 
3.1 Method development 16 
The number of anthelminthic drugs in human medicine is very limited and no candidates 17 
are currently in the pipeline. Drug resistance on anthelminthics has been already observed in 18 
veterinary medicine,33–35 a development that must be prevented in humans. Ivermectin with 19 
its broad antiparasitic activity is a promising candidate for the treatment of STH infections. 20 
However, proper scientific information is missing on efficacy, safety, PK and –21 
pharmacodynamics, particularly for STH infections. Several articles describe the analytical 22 
quantification of ivermectin extracted from animal or human plasma or food samples by 23 
HPLC mostly detecting a fluorescent counterpart of the drug,13,25,36 in which ivermectin does 24 
not get separated from its metabolites. The PK profiles of the metabolites remain unknown 25 
and most likely differ from ivermectin’s characteristics.13,37,38 Additionally, other analytical 26 
approaches have been tested such as capillary electrophoresis or gas chromatography.39,40  27 
LC-MS/MS is the gold standard for quantifying individual analytes. Two articles describe 28 
the analysis of ivermectin by mass spectrometry in plasma, but they are not applicable to 29 
micro-blood samples because large plasma volumes are required.27,28 Ivermectin remains a 30 
challenging candidate to be quantified in DBS samples caused by the limited blood volume in 31 
combination with its low concentration in the blood after oral delivery.13,15 This is due to its 32 
moderate bioavailability and the low dose of treatment. Additionally, ivermectin poorly ionizes 33 
in the mass spectrometer leading to low sensitivity. Based on this information, a careful and 34 
stepwise LC-MS/MS method and extraction procedure development was performed. 35 
First, the parent mass of ivermectin was tested in the positive ionization mode. The 36 
parent mass ionized with H+ (m/z 875.5 [M + H]+) could not be detected, but the ammonium 37 
(m/z 892.5 [M + NH4]
+) and sodium counterparts (m/z 897.5 [M + Na]+) were reproducibly 38 
observed. Sodium ionized molecules fragment poorly in a MS and thus, the ammonium 39 
adduct was chosen for analysis.27 SRM scans were performed with best results for 892.5 → 40 
307 m/z and 892.5 → 569 m/z fragments. Mass spectrometer source parameters were 41 
optimized to increase peak intensity (e.g., gas temperature and flow, nebulizer pressure). 42 
Thereafter, fragment specific parameters (table 1) were improved for ivermectin and the 43 
internal standard. Due to its higher peak intensity, fragment 892.5 → 307 m/z was chosen for 44 
quantification.  45 
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Subsequently, LC conditions were adjusted by testing several columns (C18, C8 and 1 
Synergy Polar-RP) with ammonium acetate buffer (mobile phase A, 0.4 mM) and acetonitrile 2 
(mobile phase B) both spiked with 0.1% formic acid. First, an isocratic method was 3 
performed followed by testing different ratios of mobile phases (20–100% mobile phase B). 4 
Highest signal intensity was achieved with a Luna C8 column (30 x 2.0 mm, 3 µm) and a 5 
gradient eluent shown in table 2 with a flow rate of 0.5 mL/min.  6 
In a next step, the extraction method of ivermectin from blood, plasma and DBS was 7 
evaluated. Plasma is the standard matrix used for PK studies. Additionally, blood samples 8 
were collected to explain possible discrepancy between ivermectin’s concentration in DBS 9 
and plasma. A classical approach was tested for plasma samples, where proteins were 10 
simply precipitated with an organic solvent. Ivermectin recovery was evaluated with 11 
acetonitrile, methanol, acetone and ethyl acetate as extraction solvents. Additionally, all 12 
solvents were tested in an aqueous mixture. Best results were achieved with a mixture of 13 
acetonitrile/H2O (4:1 v/v, ES1) and a shaking time of 10 min at rt. Longer shaking, heating 14 
and the inclusion of sonication were tested with no additional positive effect. Simple filtration 15 
did not lead to a highly purified analyte solution and a significant matrix effect was observed. 16 
Thus, SPE was performed to maximize signal intensity in the mass spectrometer.  17 
The same extraction method was performed with blood samples. Blood cells and proteins 18 
could not be entirely aggregated with the extraction solvent (ES1), which caused 19 
unsatisfactory results of the SPE purification. The fraction of organic solvent was increased 20 
to 5:1 acetonitrile/H2O (v/v, ES2), which improved the purification steps and thus overall 21 
results.  22 
The punched spot size of DBS was maximized to increase the blood volume analyzed 23 
and thus ivermectin amount in the sample. The DBS cards offer a spot size of 12 mm. Blood 24 
was spotted with a capillary in a pre-test after pricking a finger to evaluate which blood spot 25 
size can be used conveniently at the clinical trial site and an 8 mm spot size was 26 
consequently chosen. In order to increase signal intensity in the MS, two spots were used for 27 
analysis. Ivermectin extraction from DBS with only acetonitrile or an aqueous mixture of it did 28 
not yield satisfying results. Therefore, whole blood was first extracted from DBS with water 29 
and thereafter acetonitrile/H2O (4:1 v/v) was added to extract ivermectin. An additional 30 
sonication step further improved MS signals. SPE was performed to yield highly purified 31 
samples and to concentrate the samples to lower volume.  32 
 33 
3.2 Method validation 34 
Stability of ivermectin in plasma, blood and DBS was determined under different 35 
conditions mimicking field and laboratory work (table 3). Three QC concentrations (low, 36 
middle and high) were extracted and stored at rt for 4 h and at 4 ºC for 72 h. High accuracy 37 
was obtained with low deviation (< 11%) for all three matrixes. DBS samples (not extracted) 38 
were stored at rt for 2.5 months to evaluate its stability under the conditions at the clinical trial 39 
site when no freezer is available. Extracted samples retained high accuracy and precision 40 
(table 3). Three freeze/thaw cycles were performed with sets of samples, which were 41 
subsequently extracted and analyzed. Ivermectin was proven stable in plasma and DBS with 42 
high accuracy and precision (CV: 0.9–7%). Spiked blood samples kept under the latter 43 
condition yielded ineligible accuracy (81.3–108%, required range: 85–115%) with low 44 
precision (CV: ≤ 22%). Additionally, long term stability was tested by storing samples for 2–3 45 
months at -80 ºC. Ivermectin in plasma and DBS samples retained stability, whereas blood 46 
samples did not achieve acceptable accuracy and precision (CV > 15%). Thus, ivermectin 47 
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samples were found stable under all conditions in plasma and DBS, but storage of blood 1 
samples did not yield the required accuracy and precision and thus, failed the validation. 2 
Therefore, blood samples were not further evaluated in this work and conclusively, blood is 3 
not the matrix of choice when ivermectin is analyzed.  4 
5 
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 1 
Table 3. Stability of ivermectin in plasma, blood and DBS.  2 
Condition Matrix 
cnominal 
[ng/mL] 
cø 
[ng/mL] 
Accuracy ± CV 
[%] 
 
Room 
temperature  
(4 h, extracted) 
 
 
 
Room 
temperature  
(2.5 months) 
Plasma 003 2.88 96.0 ± 10.9 
 100 114  114 ± 1.17 
 180 198  110 ± 0.42 
Blood 005 5.01  100 ± 2.42 
 100 97.1 97.1 ± 6.19 
 180 188.1  105 ± 4.26 
DBS 005 4.73 94.6 ± 8.06 
 100 101  101 ± 5.08 
 180 160 88.7 ± 3.22 
 
4 ºC  
(72 h, extracted) 
Plasma 003 2.97 99.0 ± 3.62 
 100 98.2 98.2 ± 1.73 
 180 173 95.8 ± 0.28 
Blood 005 5.35  107 ± 4.04 
 100 102  102 ± 5.88 
 180 183 99.2 ± 0.83 
DBS 005 5.10  102 ± 5.60 
 100 102  102 ± 8.44 
 180 179 99.4 ± 8.61 
 
-80 ºC  
(2–3 months) 
Plasma 003 2.77 92.2 ± 1.56 
 100 101  101 ± 0.65 
 180 185  103 ± 1.56 
Blood 005 4.89 97.7 ± 15.5 
 100 103  103 ± 7.13 
 180 198  110 ± 19.0 
DBS 005 5.09  102 ± 3.00 
 100 102  102 ± 5.86 
 180 169 93.7 ± 6.37 
 
Freeze/thaw 
cycles 
(3x) 
Plasma 003 3.00  100 ± 0.92 
 100 110  110 ± 2.29 
 180 185  103 ± 1.83 
Blood 005 4.68 93.5 ± 0.88 
 100 81.3 81.3 ± 22.1 
 180 108  108 ± 1.96 
DBS 005 5.08  102 ± 7.04 
 100 102  102 ± 0.93 
 180 165 91.7 ± 5.39 
a Values are means of n = 3 different human sources 3 
 4 
The validation of selectivity and sensitivity was performed by analyzing six different blank 5 
and zero blank (without and with internal standard, respectively) human plasma and DBS 6 
samples and their corresponding LLOQs. Representative LC-MS/MS chromatograms of zero 7 
blank samples are illustrated in figure 2 including the LLOQ of each matrix for comparison 8 
(892.5 → 307 m/z). Zero blank samples were extracted with the internal standard to exclude 9 
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that deuterated ivermectin partially contains ivermectin. No co-elution of unidentified peaks 1 
was observed proving the selectivity of the method and the purity of deuterated ivermectin 2 
(figure 2). The sensitivity of the method is defined by the LLOQ; 2 ng/mL and 3 ng/mL was 3 
achieved for plasma and DBS, respectively. The signal to noise ratio was at least 5:1 for the 4 
analytes as specified by the U.S. FDA guidelines for method’s sensitivity. 5 
Linearity of the method was tested in 2–200 ng/mL range for plasma and 3–200 ng/mL 6 
for DBS. Higher blood concentration of ivermectin was not expected due to earlier reported 7 
data of healthy volunteers.13,15 75% of calibration samples did not deviate more than ± 15% 8 
(LLOQ: ± 20%) from the nominal value. The correlation coefficient (r2) of all validation 9 
experiments was > 0.997.  10 
Accuracy and precision were tested in validation experiments. Intra-assay results were 11 
determined by analyzing three validation sets on one day and inter-assay experiments were 12 
performed with three validation sets on three individual days. In all sets, four QC 13 
concentrations were evaluated in six different human sources and compared to the 14 
calibration line (ntot = 18 QC samples). At least 4/6 QC samples were in line with the 15 
regulations (± 15% of the nominal value, ± 20% for the LLOQ). Intra and inter assay results 16 
of the two matrixes (plasma and DBS) are similar with an accuracy of 96.3–101% and 96.1–17 
107% and a precision of 3.79–12.2% and 4.89–12.2%, respectively (table 4). The consistent 18 
accuracy and precision < 15% prove the method’s validity for the two matrixes. Moreover, 19 
varying hematocrits of DBS samples did not affect results.  20 
 21 
 22 
Figure 2. Background signal of four zero blank matrix samples: (A) plasma, (B) DBS. LC-MS/MS chromatograms 23 
of 892.5 → 307 m/z are presented when pure matrix was extracted. Internal standard was added to all zero blank 24 
samples to exclude interference of ivermectin detection by the internal standard. The chromatogram of the LLOQ 25 
is shown for comparison. The LLOQ of 2 ng/mL was achieved for plasma and 3 ng/mL for DBS. 26 
27 
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 1 
Table 4. Intra- and inter-assay accuracy and precision of ivermectin extracted from plasma 2 
and DBS.  3 
Matrix 
cnominal 
[ng/mL] 
Intra-assaya Inter-assaya 
cø 
[ng/mL] 
Accuracy ± 
CV [%] 
cø  
[ng/mL] 
Accuracy ± 
CV [%] 
Plasma 
222 1.93 96.3 ± 8.24 1.93 96.6 ± 6.82 
003 2.97 99.1 ± 12.2 3.02  101 ± 8.20 
 100 97.6 97.6 ± 7.43 99.1 99.1 ± 3.79 
 180 177 98.1 ± 6.47 178 99.0 ± 4.07 
DBS 003 3.13  104 ± 12.2 3.21  107 ± 11.7 
     5 4.88 97.5 ± 10.6 4.80 96.1 ± 9.89 
 100 98.2 98.2 ± 5.68 99.4 99.4 ± 4.89 
 180 180  100 ± 8.08 179 99.6 ± 7.83 
a Values are means of n = 18 QC samples of three independent validation sets. 4 
 5 
The RRE and ME of ivermectin extracted from plasma and DBS were determined in three 6 
concentrations (low, middle and high) and results are illustrated in table 5. No ME were 7 
observed for the two matrixes with results > 88% and the coefficient of variation was low for 8 
DBS (< 6%) and plasma samples (< 11%).  9 
RRE of ivermectin resulted in acceptable values for plasma (> 77%) with low deviation. 10 
RRE of DBS yielded in consistent but rather low results (47–56%). The low RRE might be 11 
caused by the extraction procedure, where two spots are extracted in one Eppendorf Tube®. 12 
The two DBS spots tended to stick together during extraction so that the solvents possibly 13 
could not reach effectively both sites of both spots. For future studies, the extraction 14 
procedure should be further optimized to increase RRE results.  15 
 16 
Table 5. Relative recovery (RRE) and matrix effect (ME) of ivermectin extracted from plasma 17 
and DBS.  18 
Matrix 
cnominal 
[ng/mL] 
RRE ± CV 
[%]a 
Mean ± CV 
[%]b 
ME ± CV 
[%]a 
Mean ± CV 
[%]b 
Plasma 003   85 ± 13 81 ± 9.2    97 ± 11 92 ± 8.3 
 100   77 ± 7.6     91 ± 6.5  
 180   81 ± 2.2     88 ± 1.3  
DBS 005   56 ± 1.5 52 ± 3.4    102 ± 3.75 106 ± 4.88 
 100   47 ± 6.2     107 ± 1.83  
 180   53 ± 8.2     107 ± 6.18  
a Values are means of n = 4 different human sources 19 
b Values are means of n = 12 samples (3 concentrations measured in 4 human sources) 20 
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 1 
Figure 3. Representative LC-MS/MS chromatograms of ivermectin (892.5 → 307 m/z, black line) with internal 2 
standard (dashed line) extracted from (A) plasma and (B) DBS samples from the identical patient 4 h post-3 
treatment. 4 
  5 
3.3 Method application 6 
The LC-MS/MS method was applied to samples collected from 11 T. trichiura infected 7 
adult volunteers treated with 200 µg/kg ivermectin in a clinical study in rural Côte d’Ivoire. 8 
Ivermectin was extracted from plasma and DBS samples and representative LC-MS/MS 9 
chromatograms of ivermectin are shown in figure 3. The concentration-time profiles (figure 10 
4A) illustrate that the time to reach maximum ivermectin concentration is identical for plasma 11 
and DBS samples (tmax = 3.9 h, table 6). A slow clearance and thus a long t1/2 (26 and 32 h, 12 
respectively) was observed for plasma and DBS samples as ivermectin was still detectable 13 
after 72 h post-treatment. The detected median of the maximal ivermectin concentration 14 
(Cmax) was 51.6 ng/mL (26.7–91.2 ng/mL) and 40.1 ng/mL (22.6–64.3 ng/mL) for plasma and 15 
DBS samples, respectively (table 6). The evaluated AUC is 987 ng/ml*h for plasma and 16 
810 ng/ml*h for DBS samples. No statistical significant difference was observed between the 17 
PK parameters of the two matrices. Moreover, Bland-Altman analysis was performed to 18 
evaluate the statistical deviation between the quantified ivermectin concentrations in plasma 19 
and DBS samples (figure 4B). Consistent and good agreement was obtained of plasma/DBS 20 
samples since most data are within confidence intervals (± 95%).  21 
 22 
 23 
 24 
Figure 4. (A) Concentration time profile of ivermectin extracted from plasma and DBS. LLOQ for DBS (3 ng/mL) 25 
is shown as a black line. (B) Bland-Altman analysis comparing results of plasma and DBS clinical trial samples. 26 
95% confidence intervals are shown as dashed lines. Bias is illustrated as a black line.  27 
Page 14 of 19Analytical Methods
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A
na
ly
tic
al
M
et
ho
ds
A
cc
ep
te
d
M
an
us
cr
ip
t
15 
 
 1 
Table 6. Pharmacokinetic parameters of ivermectin extracted from plasma and dried blood 2 
spots (DBS). No statistical significant difference between parameters derived from plasma 3 
and DBS samples was reported (p < 0.05). 4 
Matrix  
t1/2  
[h] 
tmax  
[h] 
Cmax  
[ng/mL] 
AUC  
[ng/ml*h] 
Plasma 
 
Median 
Min 
Max 
26.2 
12.1 
66.1 
3.9 
2.1 
9.1 
51.6 
26.7 
91.2 
987 
511 
2199 
DBS 
Median 
Min 
Max 
32.3 
17.8 
84.2 
3.9 
2.3 
9.2 
40.1 
22.6 
64.3 
810 
348 
1664 
 5 
4. Conclusion 6 
A rapid, robust and sensitive LC-MS/MS method was established to quantify ivermectin 7 
extracted from DBS and plasma. Accuracy, precision, selectivity and sensitivity fulfilled the 8 
requirements defined by U.S. FDA for DBS, plasma and blood samples, but ivermectin was 9 
proven stable under several conditions only in DBS and plasma. Thus, the method validation 10 
was accomplished with consistent results for plasma and DBS but partially failed for blood 11 
samples. When the method was applied to PK clinical trial samples from T. trichiura infected 12 
adults, identical tmax and similar Cmax, t1/2 and AUC were obtained for plasma and DBS 13 
samples. DBS should therefore be the matrix of choice for future clinical trials, especially 14 
when children are volunteering. This allows a more ethical and less invasive procedure for 15 
patients and an easier and consistent technique for field and laboratory work.  16 
 17 
18 
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